drugset / Trial / NCT01870687

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

NCT01870687 ↗

Phase 3 Terminated 96 enrolled Bionorica SE
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to proof the efficacy and safety of 20 mg (2 tablets of 10 mg) VAC BNO 1095 film-coated tablets in patients suffering from cyclic mastodynia and PMS (pre menstrual syndrome).

Timeline

Start
2013-06
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject VAC BNO 1095 Unknown 20 mg Oral